Evidence map›Paper›PMID 35335032›Full record

ArticleVaccines2022

Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study.

José Francisco Muñoz-Valle, Gabriela Athziri Sánchez-Zuno, Mónica Guadalupe Matuz-Flores, Cristian Oswaldo Hernández-Ramírez, Saúl Alberto Díaz-Pérez, Christian Johana Baños-Hernández, Francisco Javier Turrubiates-Hernández, Alejandra Natali Vega-Magaña, Jorge Hernández-Bello

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

José Francisco Muñoz-ValleInstitute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0002-2272-9260
Gabriela Athziri Sánchez-ZunoInstitute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0002-4390-8604
Mónica Guadalupe Matuz-FloresInstitute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.
Cristian Oswaldo Hernández-RamírezInstitute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0003-1082-0734
Saúl Alberto Díaz-PérezInstitute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0003-3225-5174
Christian Johana Baños-HernándezInstitute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0002-5424-1921
Francisco Javier Turrubiates-HernándezInstitute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0001-9637-168X
Alejandra Natali Vega-MagañaInstitute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0003-4749-2498
Jorge Hernández-BelloInstitute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0001-8004-1811
Universidad de Guadalajara · MX

Funding

CONCURRENCIAS FINANCIERAS PARA LA INVESTIGACIÓN Y ATENCIÓN DE LA VIN-CULACIÓN program 260761
6 · The paper itself

Abstract

Several studies have reported the benefits and safety of heterologous vaccination among different approved vaccines; however, there are no specific reports on the effects of vaccination with the Ad5-nCoV and other vaccines of the same or different technologies. In the present study, we evaluated the neutralizing antibodies percentage against SARS-CoV-2 in Mexican patients immunized with the Ad5-nCoV vaccine six months after its application. Moreover, the effect of the heterologous vaccination with the Ad5-nCoV vaccine and a booster dose of ChAdOx1-S-Nov-19, Ad26.COV2.S, BNT162b2, or mRNA-127 were determined. Our results suggest that a heterologous regimen of one dose with Ad5-nCoV vaccine followed by a booster dose of a different vaccine is safe and induces a stronger humoral immune response.

Indexed as

antibodiesboosterCOVID-19SARS-CoV-2vaccination

Identifiers

PMID35335032
PMCPMC8954152
OpenAlexW4220803810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.